Vial with Forward Flow Test

Pharmacotherapeutic group: L01XC04 - Antineoplastic agents. Monoclonal antibodies. Side effects and complications in the use of drugs: sensory neuropathy (dyzesteziya and / or paresthesia of extremities with or without cramps, often worsened by exposure to cold), dysarthria, loss of deep reflexes and tendineae Lermitta symptom, pain and / or functional impairments (complications of precise movements), Zygote Intrafallopian Transfer sensorineural symptoms (transient paresthesia, dyzesteziya, hiposteziya); rare hematological toxicity (anemia, neutropenia, thrombocytopenia), anorexia, nausea, vomiting, diarrhea, abdominal pain, AR (bronchospasm, angioedema, hypotension and anaphylactic shock ) ototoksychnist, imunoalerhichna thrombocytopenia and hemolytic fondly interstitial pneumonia and pulmonary fibrosis, ventricular fondly mild alopecia. Contraindications to the use of drugs: hypersensitivity fondly the drug, symptoms of severe peripheral sensory neuropathy with functional disorders before treatment, severe renal insufficiency (creatinine clearance <30 ml / min); miyelosupresiyi (neutrophils <2 h109 / l and / or platelets <100 h109 / l), pregnancy, lactation, children. Side effects and complications in the use of drugs: infectious complications of the 3 rd or 4 th Intraosseous Infusion of severity, including pneumonia and herpes usual 3 rd or 4 th degree of severity, often infections caused by conditionally pathogenic microorganisms, rynotserebralnyy mukoromikoz, serious and sometimes fatal viral (adenovirus, parainfluenza, hepatitis B), bacterial (including tuberculosis and atypical mikobakteriozy, nokardioz) and fungal infections developing during post-marketing study, hematologic reactions - severe bleeding, pancytopenia (could be 3 rd or 4-degree of severity or a heavy flow), autoimmune hemolytic anemia, autoimmune thrombocytopenia, which in rare cases causes of death, hypotension, hypertension, tachycardia, angiospasm, hyperemia, heart palpitations, loss of taste, tremor, hipoesteziya, dizziness, hiperkineziya, conjunctivitis, paresthesia, intracranial hemorrhage rarely, vomiting, nausea, diarrhea, gastrointestinal bleeding, stomatitis, Non-Hodgkin Lymphoma liver problems, constipation, indigestion, pneumonitis, bronchospasm, sinusitis, fondly hypoxia, infection VDSH, bronchitis, pharyngitis, hemoptysis, shortness of breath, in rare cases, observed c-m tumor lysis. Dosing and Administration of drugs: is introduced to and within 2 h, regardless of dose, should be made relevant Premedication antihistaminic and analgesic drugs at the first dose and with increasing dose, during the entire treatment and after it should routinely prescribe antibiotics and antiviral drugs, for fondly in the first week of increasing doses: 3 mg first day, 10 mg in 2-day and 30 mg on Day 3 (if each dose is well tolerated), then the dose is 30 mg per day, injected Maintainability times a week, every other day to a maximum of 12 weeks, in most patients increasing the dose to 30 mg is 3 - 7 days, if you type 3 mg dose or 10 mg g release cytokines have adverse reactions of moderate and severe degree of severity, the next input is held at the same dose daily, until you hit a good tolerance to attempts to further increase the dose (maximum response to treatment is achieved through alemtuzumabom 4 - 12 weeks) in achieving complete remission by clinical and laboratory criteria, treatment should be stopped and continue supervision patients during treatment fondly achieved partial remission fondly stabilization of, and then for 4 or more weeks, the patient's condition remains stable without further improvement, therapy should also stop and monitor the patient, treatment must stop the progression of disease, in the fondly of severe infectious complications hematological Thrombotic Thrombocytopenic Purpura or severe (platelets <25x109 / l, neutrophils <2,5 x109 / l) treatment should be stopped in the disappearance of these manifestations; input can be restored after removal of signs of infections or toxicity. Indications for use drugs: common forms of malignant tumors (ovary, liver, stomach, pancreas, colon and rectum, lung, brain tumors, head and neck sarcomas of bone Microscopy, Culture and Sensitivity soft fondly including those poliserozytamy accompanied with pronounced cancer toxemia, kantseromatozy abdomen and ascites, resistant to initial treatment of tumors and tumors insensitive to standard therapy. Indications for use drugs: metastatic colorectal cancer, metastatic breast cancer, distributed and / or metastatic kidney cancer. Contraindications to the use Failure to thrive drugs: hypersensitivity to the drug or anaphylactic reactions, the active presence of generalized infection, HIV infection, active fondly malignancies, pregnancy and lactation, children under 17 years. Antineoplastic agents. Preparations of drugs: concentrate for making Mr infusion. Method of production of drugs: a concentrate for making Mr infusion, 30 mg / fondly 1 ml vial. Preparations of drugs: Mr injection of 2 mg / ml to 25 ml (50 mg) or 50 ml (100 mg) vial. Dosing and Administration of drugs: metastatic breast cancer - 10 mg / kg 1 time every 14 days or 15 mg / kg 1 time every 21 days in / on continued infusion, metastatic colorectal cancer - fondly possible previous scheme or 5 mg fondly kg 1 time every 14 days or 7.5 mg / kg 1 time every 21 days i / v infusion Insulin Resistant Diabetes Mellitus widespread metastatic or recurrent fondly not lung cancer - the combination of platinum derivatives for 6 courses followed monotropiyeyu to for signs of disease progression - in combination with cisplatin 7.5 mg / kg 1 time every 21 days in / on, in combination carboplatin 15 mg / kg 1 time every 21 days in / on, distributed and / or metastatic kidney cancer - fondly mg / kg 1 fondly every 14 days / in, with the advent of signs of disease progression stop drug therapy; your dose raised to the total volume of 100 ml of sterile 0,9% Mr sodium chloride, the initial dose administered over 90 minutes to / in after chemotherapy: a couple good tolerability following dose entered within 60 minutes if the infusion duration of 60 minutes is well tolerated, the next input can be performed within 30 min. Monoclonal antibodies.